Case Report
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2005; 11(24): 3803-3805
Published online Jun 28, 2005. doi: 10.3748/wjg.v11.i24.3803
Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization
Yong-Song Guan, Yuan Liu, Long Sun, Xiao Li, Qing He
Yong-Song Guan, Yuan Liu, Long Sun, Xiao Li, Qing He, Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuang Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Yong-Song Guan, Department of Radiology, West China Hospital, Sichuan University, 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China. yongsongguan@yahoo.com
Telephone: +86-28-85421008 Fax: +86-28-85421008
Received: August 31, 2004
Revised: September 1, 2004
Accepted: October 18, 2004
Published online: June 28, 2005
Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). But this method has some shortages. p53 gene, which was found to be mutant in many human tumors, has been proved with broad-spectrum anti-tumor effects. We reported a 23-year-old patient with recurrent HCC after irregular hepatectomy. The p53 gene was applied to this patient. We injected percutaneously and infused transcatheterally p53 gene (Gendicine, Shenzhen Sibiono Bentech, China) into his recurrent nodules in liver respectively and 4 d later, the patient received TACE therapy. In the 2 mo follow-up, the patient was in good clinical condition with normal liver function and no recurrence was identified. The case report proposed that recurrent HCC could be successfully treated with p53 gene therapy combining TACE.

Keywords: Hepatocellular carcinoma; Transcatheter arterial chemoembolization; p53 gene